PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.
Adult Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid or gluteal IM inj; alternate sides. Give with oral risperidone (or other antipsychotic) for ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of ...
The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...
Rykindo ® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma's Central Nervous System (CNS) product portfolio to be marketed in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results